PMID- 29358570
OWN - NLM
STAT- MEDLINE
DCOM- 20180813
LR  - 20220317
IS  - 1643-3750 (Electronic)
IS  - 1234-1010 (Print)
IS  - 1234-1010 (Linking)
VI  - 24
DP  - 2018 Jan 23
TI  - Long Non-Coding RNA Cancer Susceptibility Candidate 2a (CASC2a) Is a Marker of 
      Early Recurrence After Radical Cystectomy in Patients with Urothelial Carcinoma 
      of the Bladder.
PG  - 438-447
AB  - BACKGROUND The aim of this study was to investigate the expression of long 
      non-coding RNAs (lncRNA) cancer susceptibility candidate 2a (CASC2a) in patients 
      with urothelial carcinoma of the bladder (UCB) and its predictive value in the 
      recurrence of UCB after radical cystectomy (RC). MATERIAL AND METHODS Tumor and 
      paired adjacent normal tissues were obtained from 112 patients with UCB who 
      underwent RC in our hospital from March 2010 to March 2012. The expression of 
      CASC2a was evaluated by quantitative reverse transcriptase polymerase chain 
      reaction (qRT-PCR) and fluorescence in situ hybridization (FISH). RESULTS CASC2a 
      was down-regulated in UCB tissues, and was highly negatively correlated with the 
      pT, pN, tumor size, and lymphovascular invasion (LVI). The sensitivities of 
      CASC2a for diagnosing UCB and its recurrence after RC were 89.30% and 81.55%, 
      respectively, and the specificities were 71.43% and 58.21%, respectively. 
      Patients with a high expression of CASC2a had a higher 5-year recurrence-free 
      survival rate than those with low expression of CASC2a. Kaplan-Meier survival 
      analysis demonstrated that the pT, pN, tumor grade, tumor size, concomitant 
      carcinoma in situ (CIS), LVI, soft tissue surgical margin (STSM), and CASC2a 
      expression were related to the recurrence in patients undergoing RC for UCB. Cox 
      proportional hazard model analysis showed that CASC2 expression, pT4, lymph node 
      metastasis, and CIS were independent risk factors. CONCLUSIONS CASC2a was 
      down-regulated in patients with UCB, and was associated with the risk of 
      recurrence among patients undergoing RC, indicating that lncRNAs could act as 
      predictive biomarkers and potential therapeutic targets in bladder cancer, 
      including CASC2a.
FAU - Li, Zhen
AU  - Li Z
AD  - Department of Urology, The Affiliated Hospital of Hangzhou Normal University, 
      Hangzhou, Zhejiang, China (mainland).
FAU - Wang, Kang-Er
AU  - Wang KE
AD  - Department of Urology, The Affiliated Hospital of Hangzhou Normal University, 
      Hangzhou, Zhejiang, China (mainland).
FAU - Zhou, Xie-Lai
AU  - Zhou XL
AD  - Department of Urology, The Affiliated Hospital of Hangzhou Normal University, 
      Hangzhou, Zhejiang, China (mainland).
FAU - Zhou, Jin
AU  - Zhou J
AD  - Department of Urology, The Affiliated Hospital of Hangzhou Normal University, 
      Hangzhou, Zhejiang, China (mainland).
FAU - Ye, Chun-Hua
AU  - Ye CH
AD  - Department of Urology, The Affiliated Hospital of Hangzhou Normal University, 
      Hangzhou, Zhejiang, China (mainland).
LA  - eng
PT  - Journal Article
DEP - 20180123
PL  - United States
TA  - Med Sci Monit
JT  - Medical science monitor : international medical journal of experimental and 
      clinical research
JID - 9609063
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (RNA, Long Noncoding)
SB  - IM
MH  - Biomarkers, Tumor/*metabolism
MH  - *Cystectomy
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - *Genetic Predisposition to Disease
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Neoplasm Recurrence, Local/*genetics/pathology
MH  - Proportional Hazards Models
MH  - RNA, Long Noncoding/*genetics/metabolism
MH  - ROC Curve
MH  - Urinary Bladder Neoplasms/*genetics/pathology/*surgery
MH  - Urothelium/*pathology
PMC - PMC5791421
COIS- Conflicts of interest The authors declare no conflict of interest.
EDAT- 2018/01/24 06:00
MHDA- 2018/08/14 06:00
PMCR- 2018/01/23
CRDT- 2018/01/24 06:00
PHST- 2018/01/24 06:00 [entrez]
PHST- 2018/01/24 06:00 [pubmed]
PHST- 2018/08/14 06:00 [medline]
PHST- 2018/01/23 00:00 [pmc-release]
AID - 905393 [pii]
AID - 10.12659/msm.905393 [doi]
PST - epublish
SO  - Med Sci Monit. 2018 Jan 23;24:438-447. doi: 10.12659/msm.905393.